RDMD, a San Francisco, CA-based healthcare technology company dedicated to accelerating research for patients with rare diseases, raised $3m in seed financing.
The round was was led by Lux Capital, with participation from Village Global, First Round’s Healthcare Co-Op, Garuda, Shasta Ventures and various angel investors from the biotech and healthtech industry. In conjunction with the financing, Renata Quintini, partner of Lux Capital, joins as a board observer.
The company intends to use the funds to further develop its platform, expand the leadership team to support demand and growth, generate data, expand into new rare conditions, and work with partners to advance their research and development programs.
Co-founded by Onno Faber, founder, chairman and head of product; Nancy Yu, co-founder and chief executive officer, RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that allows patients and families to get access to and benefit from their own medical data.
RDMD is currently collaborating with researchers at the National Cancer Institute to track pain symptoms in people with a type of neurofibromatosis called NF1.
The company has also partnered with the Children’s Tumor Foundation to generate real world evidence from NF patient medical records across all forms of neurofibromatosis, including NF1, NF2 and schwannomatosis. RDMD plans to expand into rare neurological and inherited metabolic diseases.